ERS Genomics Ltd.. (4/3/19). "Press Release: European Patent Office Grants 3rd Charpentier/Doudna Patent Covering Uses of CRISPR/cas9 in Human and Animal Cells". Dublin.

	Region	Europe
	Organisation	ERS Genomics Ltd.
	Organisation 2	European Patent Office (EPO)
	Group	European Patent Organisation (EPO)
	Product	CRISPR gene editing technology
	Product 2	IP services
	Person	Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
	Person 2	Doudna, Jennifer (Univ California Berkeley 201412)

EPO Patent No. 3.401.400 issued to Dr. Emmanuelle Charpentier, University of California, and University of Vienna

ERS Genomics Limited announced today that the European Patent Office (EPO) has issued a new patent to Dr. Emmanuelle Charpentier, The Regents of the University of California and University of Vienna. EPO Patent No. 3,401,400 claims methods and compositions of using CRISPR/Cas9 to modify DNA and regulate gene activity in eukaryotic cells, including kits to carry out such work. ERS Genomics provides broad access to these and other foundational CRISPR/Cas9 patents co-owned by Dr. Emmanuelle Charpentier.

Eric Rhodes, CEO of ERS Genomics, said: “The most common use for CRISPR/Cas9 is in eukaryotic cells, including human and animal cells. We are pleased to have another comprehensive patent covering methods, compositions and kits for such uses which adds to our portfolio of patents which have issued in over 40 countries worldwide.”

For additional information please visit www.ersgenomics.com.

Media contact:

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About ERS Genomics www.ersgenomics.com

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.

Record changed: 2023-06-05